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At the time of reporting there were no reports of
significant hepatotoxicity involving levetiracetam in
clinical trials. There has been one reported case of a
fatal fulminant hepatic failure in a patient with re-
fractory epilepsy treated with combination carbam-
azepine and levetiracetam. Autopsy findings revealed
complete hepatocyte necrosis5 but it was unclear if
levetiracetam was the only or primary culprit in
causality.5
In our patient careful consideration has been
given toward other potential etiologies of hepatotox-
icity. Phenytoin was deemed unlikely to be the cause
due to preexisting deranged LFTs prior to commenc-
ing it and was still administered in the postoperative
period when his LFTs were improving. Azathioprine
can cause hepatotoxicity but the timing of its com-
mencement did not correlate with the recurrence of
abnormal LFTs. This very same reason applies to all
his other posttransplant medications which were
continued safely upon discharge. Oxcarbazepine and
albendazole were already ceased prior to the develop-
ment of documented hepatotoxicity making them
very unlikely culprits. None of the antimicrobials
were ceased when the patient’s LFTs deteriorated
posttransplant and its improvement thereafter was
not related to their withdrawal.
Exclusion of other possible etiologies has left leve-
tiracetam as the most likely cause of fulminant he-
patic failure in our patient. This link was further
strengthened by the inadvertent rechallenge with the
drug after post liver transplant resulting in deteriora-
tion of the LFTs and biopsy findings suggestive of a
toxic cause.
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CARRIER ERYTHROCYTE ENTRAPPED THYMIDINE
PHOSPHORYLASETHERAPYFORMNGIE
Mitochondrial neurogastrointestinal encephalomy-
opathy (MNGIE) is an autosomal recessive condi-
tion caused by mutations in the nuclear gene ECGF1
coding for thymidine phosphorylase (TP).1,2 Clinical
features include gastrointestinal dysmotility, periph-
eral sensorimotor polyneuropathy, progressive exter-
nal ophthalmoplegia, and hepatopathy. In vitro
evidence and the improvement following stem cell
transplantation (alloSCT) in one patient suggest the
pathogenesis centers on elevated systemic levels of
the TP substrates, thymidine (Thd) and deoxyuri-
dine (dUrd).3,4
Case report. In September 2005, a 21-year-old
woman presented after a 4-week history of pro-
gressive bilateral distal lower limb numbness and
foot drop. She had bouts of unexplained gastroin-
testinal symptoms and weight loss since age 6 years
and at 19 developed an acute abdomen leading to
a laparotomy that revealed gross small bowel dis-
tension (thought to be caused by an elevated liga-
ment of Treitz) and hepatosplenomegaly. A
gastrojejunostomy was performed.
On neurologic examination, the positive findings
were subtle pigmentary retinopathy, partial ptosis,
slight reduction of eye abduction, markedly slow
horizontal saccades, severe weakness of ankle move-
ments, absent muscle stretch reflexes and plantar re-
flexes, and stocking diminution for light touch and
pain (all findings bilateral and symmetric). Of note
on systemic examination: underweight, gross hepato-
splenomegaly, tachycardia, and hyperdynamic car-
diac apex.
Her parents were not related. She left higher edu-
cation in autumn 2005 due to her illness.
After the laparotomy, investigations including
hepatitis serology and serum copper were normal; a
liver biopsy revealed steatohepatitis. A brain MRI
was normal except equivocal diffuse high T2 signal
in the centrum semiovale bilaterally.
Following the initial presentation, abnormal re-
sults included normochromic normocytic anemia;
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CSF lactate 5.6 mmol/L; plasma Thd 13 mol/L
and dUrd 16 mol/L (normal: both 0.05 mol/
L); urine Thd and dUrd 1.94 mmol/L and dUrd
1.95 mmol/L (normal: both undetectable); TP activ-
ity measured by HPLC was undetectable in leuko-
cytes and platelets (ranges for controls expressed as
nmol/hour/mg prot: leukocytes 321–1,341; platelets
377–1,078). Mitochondrial DNA analysis of blood
cells for 3243G and 8993TC/G was negative.
Nerve conduction studies confirmed a generalized
sensorimotor polyneuropathy. Abdomen CT showed
gross hepatosplenomegaly with marked hepatic ste-
atosis and nodularity.
Analysis of ECGF1 in blood cells demonstrated a
homozygous mutation of the conserved AG nucleo-
tide of the 3=-splice site of intron 2 corresponding to
IVS3-1GC.
Through 2006, she was increasingly unwell, with
neuropathic upper limb involvement and worsening
abdominal symptoms. She required TPN and subse-
quently a nasojejunal tube due to gastroparesis. Blood
results showed albumin 27 g/L, INR 1.16, bilirubin 8
mmol/L, ALP 135IU/L, AST 92IU/L, and GGT
129IU/L. She required recurrent paracentesis for mas-
sive ascites and developed hematemesis from esophageal
varices which were banded.
Treatment. Approval for a trial of carrier erythro-
cyte entrapped thymidine phosphorylase therapy
(CEETP) was given by the local New Clinical Proce-
dures Committee, local Ethics Committee, and Ad-
ministration of Radioactive Substances Advisory
Committee, UK. A patient information sheet was
provided and written informed consent obtained.
On day one, 140 mL of whole blood was collected
aseptically and the erythrocytes were loaded with TP
using the previously described hypo-osmotic dialysis
procedure.5 The washed and packed TP-loaded car-
rier erythrocytes were resuspended in an equal vol-
ume of retained plasma and returned to the patient
by slow IV infusion. The administered dose of TP
was 1,020 units encapsulated within 20.25  1010
erythrocytes (where 1 unit of TP is defined
as the activity required to convert 1.0 mol of
Thd and phosphate to thymine and 2-deoxyribose
1-phosphate per minute at 25°C).
Pretreatment and serial postinfusion blood sam-
ples and 24-hour urine collections were made.
Results. Three days postinfusion (figure), the uri-
nary excretion of Thd was 6% and that of dUrd 13%
of the pretherapy values. The plasma concentrations
decreased in parallel. Unfortunately, the patient’s
clinical condition remained poor and she died of
pneumonia 21 days after CEETP.
Discussion. CEETP was associated with marked re-
duction of plasma and urine Thd and dUrd. Al-
though these metabolites can fluctuate widely in
patients with MNGIE, the consistency of the fall
would suggest a causal relationship with the adminis-
tered CEETP. The results are encouraging, particu-
larly as a low dose was administered. An observed
clinical effect was unlikely given advanced disease
and the use of a single treatment.
We had discounted alloSCT and liver transplant
because of an unacceptable mortality risk due to the
patient’s severe clinical state. Autologous erythro-
cytes encapsulated adenosine deaminase has been
used successfully in a patient with adenosine deami-
nase deficiency.6,7 The approach is applicable to dis-
orders where the erythrocyte membrane is permeable
to target plasma metabolites. Encapsulation prevents
the formation of neutralizing antibodies and main-
tains enzyme activity for the erythrocyte life span.
We hypothesize that a reduction of Thd and dUrd in
the plasma would lead to similar reductions in the
intracellular compartment, as observed in other con-
ditions, thus translating into clinical improvement.
Our previous in vivo survival studies demon-
strated an initial splenic sequestration of carrier
erythrocytes, followed by a reflux into the circulation
Figure Plasma and urine metabolite values
before and after CEETP infusion
Normal ranges: plasma deoxyuridine0.05 mol/L; plasma
thymidine 0.05 mol/L; urine deoxyuridine undetectable;
urine thymidine undetectable.
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24 to 144 hours postinfusion; this may contribute to
the fluctuations observed in plasma metabolite con-
centrations.5 The disjunction of the plasma metabo-
lites at day 14 is based on a single observation; this
might be explained by saturation of the erythrocyte
membrane nucleoside transporter.
The main safety consideration was of an immuno-
logic reaction to bacterial TP or endotoxins. Endotoxin
levels were within pharmaceutical safe levels. Our previ-
ous experience with adenosine deaminase indicates im-
munologic protection with encapsulation within carrier
erythrocytes, but we cannot exclude the possibility fol-
lowing repeated administrations.
CEETPmay be a promising treatment forMNGIE.
However, repeated administration, probably two to
four weekly and potentially lifelong, would be required,
with costs not too dissimilar to other enzyme replace-
ment therapies ($200,000 per year). The frequency of
administration is likely to be influenced by many fac-
tors, particularly the severity of TP dysfunction and
erythrocyte half life. The latter was satisfactory in the
current case despite massive splenomegaly. The clinical
utility of reducing Thd and dUrd concentrations re-
mains largely theoretical. Carrier erythrocyte entrapped
TP enzyme therapy offers the opportunity to impose a
period of lowered Thd and dUrd concentrations during
which any clinical benefit can be assessed before consid-
ering alloSCT.
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